Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy

Heard, Christopher, Chaboyer, Wendy, Anderson, Vinah, Gillespie, Brigid M. and Whitty, Jennifer A. ORCID: https://orcid.org/0000-0002-5886-1933 (2017) Cost-effectiveness analysis alongside a pilot study of prophylactic negative pressure wound therapy. Journal of Tissue Viability, 26 (1). 79–84.

Preview

PDF (POSTPRINT_JTV Jun16) - Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (187kB) | Preview

Abstract

Background Negative pressure wound therapy (NPWT) is increasingly used prophylactically following surgery despite limited evidence of clinical or cost-effectiveness. Objective: To evaluate whether NPWT is cost-effective compared to standard care, for the prevention of surgical site infection (SSI) in obese women undergoing elective caesarean section, and inform development of a larger trial. Methods: An economic evaluation was conducted alongside a pilot randomised controlled trial at one Australian hospital, in which women were randomised to NPWT (n = 44) or standard care (n = 43). A public health care provider perspective and time horizon to four weeks post-discharge was adopted. Cost-effectiveness assessment was based on incremental cost per SSI prevented and per quality-adjusted life year (QALY) gained. Results: Patients receiving NPWT each received health care costing AU$5887 (±1038) and reported 0.069 (±0.010) QALYs compared to AU$5754 (±1484) and 0.066 (±0.010) QALYs for patients receiving standard care. NPWT may be slightly more costly and more effective than standard care, with estimated incremental cost-effectiveness ratios (ICERs) of AU$1347 (95%CI dominant- $41,873) per SSI prevented and AU$42,340 (95%CI dominant- $884,019) per QALY gained. However, there was considerable uncertainty around these estimates. Conclusions: NPWT may be cost-effective in the prophylactic treatment of surgical wounds following elective caesarean section in obese women. Larger trials could clarify the cost-effectiveness of NPWT as a prophylactic treatment for SSI. Sensitive capture of QALYs and cost offsets will be important given the high level of uncertainty around the point estimate cost-effectiveness ratio which was close to conventional thresholds. Australian and New Zealand trial registration number: ACTRN12612000171819.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	Pure Connector
Date Deposited:	08 Jun 2016 16:00
Last Modified:	22 Oct 2022 01:15
URI:	https://ueaeprints.uea.ac.uk/id/eprint/59271
DOI:	10.1016/j.jtv.2016.06.001

Actions (login required)

View Item